2024
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Research & Care 2024, 12: e004431. PMID: 39366717, PMCID: PMC11459310, DOI: 10.1136/bmjdrc-2024-004431.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseGLP-1Type 2 diabetesIncident useGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCardiovascular diseasePrevalence of atherosclerotic cardiovascular diseaseASCVD diagnosisProportion of patientsRetrospective observational studyNested cohort studyReceptor agonistsSGLT2i useAnalysis of cross-sectional dataSodium-glucoseCohort studyPatient numbersObservational studyPatientsPrevalent useCross-sectional dataT2D
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2021
Black Patients with Ischemic Stroke and Hyperglycemia have Worse outcome than Whites if given Intensive Glucose Control
de Havenon A, Muddasani V, Castillo M, Sheth KN, Delic A, Herman A, Conaway M, Johnston KC, Investigators F. Black Patients with Ischemic Stroke and Hyperglycemia have Worse outcome than Whites if given Intensive Glucose Control. Journal Of Stroke And Cerebrovascular Diseases 2021, 30: 106065. PMID: 34455151, PMCID: PMC8511272, DOI: 10.1016/j.jstrokecerebrovasdis.2021.106065.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanHealth Status DisparitiesHumansHyperglycemiaHypoglycemic AgentsIschemic StrokeTreatment OutcomeWhite PeopleConceptsIntensive glucose controlAcute ischemic strokeWorse functional outcomeBlack patientsGlucose controlIschemic strokeWhite patientsExcellent outcomesFunctional outcomeTreatment armsWorse outcomesAcute ischemic stroke patientsStroke Hyperglycemia Insulin Network Effort (SHINE) trialIntensive treatment armStandard treatment armIschemic stroke patientsExcellent functional outcomeMixed effects logistic regression modelsLogistic regression modelsPrimary outcomeStroke patientsPotential confoundersOdds ratioFunctional impairmentPatients